Please assess the completion status of the following clinical trial:

Trial Title: Abatacept Versus Adalimumab Head-to-Head

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria~* Methotrexate failure~* Naive to RA biologics~* ≤5 years duration of disease~* Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2~* Willingness to self-inject subcutaneous (SC) drug~Exclusion Criteria:~* Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents~* History of active or chronic hepatitis~* Cancer in the last 5 years~* History of severe chronic or recurrent bacterial or viral infections~* Risk of tuberculosis~* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): None
- Adalimumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).